Fennec Pharmaceuticals Inc.

NasdaqCM FENC

Fennec Pharmaceuticals Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 40.32 M

Fennec Pharmaceuticals Inc. Cash and Short-Term Investments is USD 40.32 M for the quarter ending September 30, 2024. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqCM: FENC

Fennec Pharmaceuticals Inc.

CEO	Mr. Rostislav Raykov
IPO Date	Sept. 15, 2017
Location	United States
Headquarters	68 TW Alexander Drive
Employees	29
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Key trends

Past 5 years